全文获取类型
收费全文 | 524篇 |
免费 | 30篇 |
国内免费 | 7篇 |
专业分类
耳鼻咽喉 | 1篇 |
儿科学 | 7篇 |
妇产科学 | 4篇 |
基础医学 | 54篇 |
口腔科学 | 5篇 |
临床医学 | 86篇 |
内科学 | 78篇 |
皮肤病学 | 9篇 |
神经病学 | 30篇 |
特种医学 | 159篇 |
外科学 | 54篇 |
综合类 | 5篇 |
预防医学 | 18篇 |
眼科学 | 2篇 |
药学 | 37篇 |
肿瘤学 | 12篇 |
出版年
2021年 | 2篇 |
2020年 | 3篇 |
2018年 | 9篇 |
2016年 | 2篇 |
2015年 | 5篇 |
2014年 | 4篇 |
2013年 | 9篇 |
2012年 | 2篇 |
2011年 | 11篇 |
2010年 | 8篇 |
2009年 | 10篇 |
2008年 | 12篇 |
2007年 | 12篇 |
2006年 | 19篇 |
2005年 | 15篇 |
2004年 | 5篇 |
2003年 | 7篇 |
2002年 | 8篇 |
2001年 | 11篇 |
2000年 | 8篇 |
1999年 | 12篇 |
1998年 | 18篇 |
1997年 | 29篇 |
1996年 | 25篇 |
1995年 | 18篇 |
1994年 | 26篇 |
1993年 | 18篇 |
1992年 | 22篇 |
1991年 | 21篇 |
1990年 | 14篇 |
1989年 | 26篇 |
1988年 | 21篇 |
1987年 | 12篇 |
1986年 | 24篇 |
1985年 | 16篇 |
1984年 | 15篇 |
1983年 | 5篇 |
1982年 | 13篇 |
1981年 | 6篇 |
1980年 | 6篇 |
1979年 | 3篇 |
1978年 | 7篇 |
1977年 | 9篇 |
1976年 | 8篇 |
1975年 | 7篇 |
1971年 | 5篇 |
1970年 | 4篇 |
1966年 | 1篇 |
1961年 | 1篇 |
1935年 | 1篇 |
排序方式: 共有561条查询结果,搜索用时 15 毫秒
91.
92.
93.
94.
95.
The role of IL-10 in the regulation of ocular autoimmune disease was
studied in experimental autoimmune uveoretinitis (EAU) elicited in mice by
immunization with the retinal antigen interphotoreceptor retinoid binding
protein. IL-10-deficient mice were susceptible to EAU, indicating that
pathogenesis can occur without presence of IL-10. Treatment of normal mice
with IL-10 for 5 days after uveitogenic immunization ameliorated subsequent
EAU scores, and down-regulated antigen-specific production of tumor
necrosis factor-alpha and IFN- gamma. A concomitant treatment with IL-4
further reduced disease, and resulted in emergence of antigen-specific IL-4
and IL-10 production, as well as in enhancement of the IgG1 antibody
isotype. IL-4 by itself was not protective. Only IL-10, but not IL-4, was
able to inhibit the function of differentiated uveitogenic T cells in
culture. Expression of mRNA for Th1 and Th2 cytokines in the eye during the
course of EAU showed that while a Th1 pattern predominated early, IL-10
mRNA expression coincided with down-regulation of the Th1 response and
resolution of EAU. Systemic neutralization of IL-10 during the expression
phase of EAU resulted in elevated disease scores. Our results suggest that
endogenous IL-10 limits expression of EAU and may play a role in the
natural resolution of disease. The data further suggest that exogenous
IL-10 may be useful in therapeutic control of autoimmune uveitis. While
IL-10 by itself is sufficient to suppress Th1 effector development and
function, a concomitant administration of IL-4 is required to shift the
autoimmune response towards a non-pathogenic Th2 pathway.
相似文献
96.
Life expectancy in British Marfan syndrome populations 总被引:2,自引:0,他引:2
JR Gray AB Bridges RR West L. McLeish AG Stuart JCS Dean MEM Porteous M. Boxer SJ Davies 《Clinical genetics》1998,54(2):124-128
A total of 206 patients with Marfan syndrome were ascertained throughout genetic clinics in Wales and Scotland during the period 1970–1990. There were 45 deaths representing 22% of the cohort. Mean age at death was 45.3 ± 16.5 years. 50% median cumulative survival in the total cohort (n = 206) was 53 years for males and 72 years for females. Multivariate analysis confirmed severity as the best independent indicator of survival. These findings and survival curves will assist in the counselling of British families and individuals with Marfan syndrome. 相似文献
97.
98.
D. Bowsher 《Postgraduate medical journal》1997,73(864):623-629
Postherpetic neuralgia is defined as pain persisting, or recurring, at the site of shingles at least three months after the onset of the acute rash. Thus defined, at least half of shingles sufferers over the age of 65 years develop postherpetic neuralgia. In addition to increasing age, less important risk factors for postherpetic neuralgia are pain severity of acute shingles and trigeminal distribution. Postherpetic neuralgia accounts for 11-15% of all referrals to pain clinics and would, in fact, be far more effectively dealt with in primary care. Effective treatment of acute shingles by systemic antivirals at the appropriate time may have some effect in reducing the incidence of postherpetic neuralgia, making it easier to treat with tricyclics and greatly reducing scarring (25% of all cases affect the face). Pre-emptive treatment with low-dose tricyclics (ami- or nor-triptyline 10-25 mg nocte) from the time of diagnosis of acute shingles reduces the incidence of postherpetic neuralgia by about 50%. Established postherpetic neuralgia should be vigorously treated with adrenergically active tricyclics in a dose rising over two or three weeks from 10-25 mg to 50-75 mg. Positive relaxation should also be used. Carbamazepine, like conventional analgesics, is of little or no value. Failure of tricyclics to effect relief within eight weeks calls for specialist treatment. North American practitioners in particular believe that some opioids (e.g., oxycodone) may be helpful in otherwise intractable cases. 相似文献
99.
A competitive particle concentration fluorescence immunoassay (PCFIA) is described for measuring 5,10-dideaza-5,6,7,8-tetrahydrofolic acid (lometrexol; Lilly) in human serum. b-Phycoerythrin-labeled lometrexol competes with free lometrexol for binding to a limiting concentration of lometrexol-specific antibodies immobilized by a second antibody to submicrometer-diameter polystyrene particles in specially designed 96-well plates. Reaction particles are washed and concentrated onto filter membranes in the wells of the plates and the fluorescence is measured at 575 nm. The method, including sample preparation and data reduction, is automated and can be completed in less than 2 h. The assay has a standard curve maximum measurable concentration of 1000 micrograms/L and a minimum detectable concentration of 0.1 microgram/L. Analytical recovery of lometrexol in serum is quantitative at concentrations greater than 1 micrograms/L. Intra- and interassay coefficients of variation at 50 micrograms/L in serum are 7.1% (n = 9) and 7.5% (n = 33), respectively. The cross-reactivity of naturally occurring folates, folic acid analogs, and the anti-cancer agent methotrexate is minimal. We report the use of the PCFIA during Phase I clinical studies designed to evaluate the pharmacokinetics of lomextrexol after intravenous administration to cancer patients. 相似文献
100.